Paul Mampilly is the founder of the Capuchin consulting in Durma North Carolina. He has won several awards such as Templeton Foundation Investment Competition. Paul Mampilly is an MBA holder from Fordham University. He put to good use this education within the finance sector. He became an assistant portfolio manager for Bankers Trust in 1991. As he garnered more experience and expertise, he was admired by different legal firms such as ING and Deutsche Bank that hired him. Billion dollar corporations hired him after realizing that he had great potential. When holding the hedge funds manager position at Kinetics Asset management, its assets grew to $25 billions.
— Paul Mampilly (@Paul_M_Guru) November 24, 2017
Wall Street later employed Paul Mampilly. During his service at Wall Street, he felt tired of making money for the rich. According to him, he was helping the rich to become richer. The common people had no one to help them improve their finance. He was determined to make a change, and that is why he started his newsletters. As of today, he had over 60,000 subscribers to his magazine. He feels motivated for helping such a larger number of people to improve their finances. The newsletters contain sound advice and investment tips that can be used by anyone to go ahead. He is populary featured on Bloomberg TV, CNBC and Fox Business.
Recently Paul Mampilly made a tease that triggered intense debate on the stock market. It was an advert on what he believed to be the biggest innovation in the medical history; what scientist believes could be a breakthrough in human medicine. The discovery was a mapping of the human DNA to find out which disease the person is at risk of getting. An appropriate treatment that the person could respond to would then be made based on their genetics. This type of medicine falls in the class of precision medicine industry.
Scientists believe that the precision industry is going to grow exponentially. If anyone buys stock in the industry, there are almost sure great returns. The company behind the discovery is Myriad Genetis (MYGN). Myriads stock has been growing in the recent, and it is expected that the trend will continue.
Paul Mampilly’s Facebook Page: www.facebook.com/PaulMampillyGuru/